12

Adjuvant chemotherapy is frequently indicated for early-stage RH+/HER2- breast cancer, according to individual and anatomo-clinical criteria and, when necessary, supported by a genomic signature. In premenopausal women (or those under the age of fifty), the benefit of ovarian function suppression (OFS) has been assessed over time using three methods: OFS as hormone therapy alone, OFS combined with tamoxifen, and OFS associated with aromatase inhibitors. A benefit in terms of overall survival is regularly observed. In addition, there is a clinical advantage to continuing hormone therapy beyond five years, depending on the anatomo-clinical risk (pT, pN); the CTS-5 score can help with this decision. The role of targeted therapies in the adjuvant setting for high-risk patients continued to be investigated, although the results obtained with abemaciclib are promising.